216 related articles for article (PubMed ID: 25955133)
1. Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy.
Pastorek M; Simko V; Takacova M; Barathova M; Bartosova M; Hunakova L; Sedlakova O; Hudecova S; Krizanova O; Dequiedt F; Pastorekova S; Sedlak J
Int J Oncol; 2015 Jul; 47(1):51-60. PubMed ID: 25955133
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells.
Duyndam MC; van Berkel MP; Dorsman JC; Rockx DA; Pinedo HM; Boven E
Biochem Pharmacol; 2007 Jul; 74(2):191-201. PubMed ID: 17498666
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.
He M; Wu H; Jiang Q; Liu Y; Han L; Yan Y; Wei B; Liu F; Deng X; Chen H; Zhao L; Wang M; Wu X; Yao W; Zhao H; Chen J; Wei M
Mol Oncol; 2019 Feb; 13(2):403-421. PubMed ID: 30536571
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane inhibits hypoxia-induced HIF-1α and VEGF expression and migration of human colon cancer cells.
Kim DH; Sung B; Kang YJ; Hwang SY; Kim MJ; Yoon JH; Im E; Kim ND
Int J Oncol; 2015 Dec; 47(6):2226-32. PubMed ID: 26498863
[TBL] [Abstract][Full Text] [Related]
5. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha.
Huang L; Ao Q; Zhang Q; Yang X; Xing H; Li F; Chen G; Zhou J; Wang S; Xu G; Meng L; Lu Y; Ma D
J Cancer Res Clin Oncol; 2010 Mar; 136(3):447-56. PubMed ID: 19760195
[TBL] [Abstract][Full Text] [Related]
7. Hypoxic tumor microenvironment in advanced retinoblastoma.
Sudhakar J; Venkatesan N; Lakshmanan S; Khetan V; Krishnakumar S; Biswas J
Pediatr Blood Cancer; 2013 Oct; 60(10):1598-601. PubMed ID: 23804414
[TBL] [Abstract][Full Text] [Related]
8. Expression of new prognostic markers, peripheral-type benzodiazepine receptor and carbonic anhydrase IX, in human breast and ovarian carcinoma cell lines.
Hunakova L; Bodo J; Chovancova J; Sulikova G; Pastorekova S; Sedlak J
Neoplasma; 2007; 54(6):541-8. PubMed ID: 17949239
[TBL] [Abstract][Full Text] [Related]
9. Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
Pucciarelli D; Lengger N; Takacova M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
Int J Oncol; 2015 Jul; 47(1):81-90. PubMed ID: 25997619
[TBL] [Abstract][Full Text] [Related]
10. IL-6 promotes nuclear translocation of HIF-1α to aggravate chemoresistance of ovarian cancer cells.
Xu S; Yu C; Ma X; Li Y; Shen Y; Chen Y; Huang S; Zhang T; Deng W; Wang Y
Eur J Pharmacol; 2021 Mar; 894():173817. PubMed ID: 33345849
[TBL] [Abstract][Full Text] [Related]
11. Sulforaphane inhibited expression of hypoxia-inducible factor-1alpha in human tongue squamous cancer cells and prostate cancer cells.
Yao H; Wang H; Zhang Z; Jiang BH; Luo J; Shi X
Int J Cancer; 2008 Sep; 123(6):1255-61. PubMed ID: 18561315
[TBL] [Abstract][Full Text] [Related]
12. Sulforaphane enhances the cisplatin sensitivity through regulating DNA repair and accumulation of intracellular cisplatin in ovarian cancer cells.
Gong TT; Liu XD; Zhan ZP; Wu QJ
Exp Cell Res; 2020 Aug; 393(2):112061. PubMed ID: 32437713
[TBL] [Abstract][Full Text] [Related]
13. CA IX is upregulated in CoCl2-induced hypoxia and associated with cell invasive potential and a poor prognosis of breast cancer.
Chu CY; Jin YT; Zhang W; Yu J; Yang HP; Wang HY; Zhang ZJ; Liu XP; Zou Q
Int J Oncol; 2016 Jan; 48(1):271-80. PubMed ID: 26648580
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional culture promotes reconstitution of the tumor-specific hypoxic microenvironment under TGFβ stimulation.
Marushima H; Shibata S; Asakura T; Matsuura T; Maehashi H; Ishii Y; Eda H; Aoki K; Iida Y; Morikawa T; Ohkawa K
Int J Oncol; 2011 Nov; 39(5):1327-36. PubMed ID: 21785823
[TBL] [Abstract][Full Text] [Related]
15. Distinct patterns of hypoxic expression of carbonic anhydrase IX (CA IX) in human malignant glioma cell lines.
Said HM; Staab A; Hagemann C; Vince GH; Katzer A; Flentje M; Vordermark D
J Neurooncol; 2007 Jan; 81(1):27-38. PubMed ID: 16944313
[TBL] [Abstract][Full Text] [Related]
16. Rapid detection of the hypoxia-regulated CA-IX and NDRG1 gene expression in different glioblastoma cells in vitro.
Said HM; Polat B; Staab A; Hagemann C; Stein S; Flentje M; Theobald M; Katzer A; Vordermark D
Oncol Rep; 2008 Aug; 20(2):413-9. PubMed ID: 18636206
[TBL] [Abstract][Full Text] [Related]
17. Modulation of cisplatin sensitivity in human ovarian carcinoma A2780 and SKOV3 cell lines by sulforaphane.
Hunakova L; Gronesova P; Horvathova E; Chalupa I; Cholujova D; Duraj J; Sedlak J
Toxicol Lett; 2014 Nov; 230(3):479-86. PubMed ID: 25159039
[TBL] [Abstract][Full Text] [Related]
18. OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition.
Nan Y; Wu X; Luo Q; Chang W; Zhao P; Zhang L; Liu Z
Proc Natl Acad Sci U S A; 2024 May; 121(19):e2315348121. PubMed ID: 38701117
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia induced CA9 inhibitory targeting by two different sulfonamide derivatives including acetazolamide in human glioblastoma.
Said HM; Hagemann C; Carta F; Katzer A; Polat B; Staab A; Scozzafava A; Anacker J; Vince GH; Flentje M; Supuran CT
Bioorg Med Chem; 2013 Jul; 21(13):3949-57. PubMed ID: 23706268
[TBL] [Abstract][Full Text] [Related]
20. Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1α in vitro.
Wang WJ; Sui H; Qi C; Li Q; Zhang J; Wu SF; Mei MZ; Lu YY; Wan YT; Chang H; Guo PT
Oncol Rep; 2016 Jul; 36(1):428-40. PubMed ID: 27221674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
